Biogened S.A.

WSE:BGD Stock Report

Market Cap: zł49.1m

Biogened Balance Sheet Health

Financial Health criteria checks 4/6

Biogened has a total shareholder equity of PLN39.3M and total debt of PLN23.3M, which brings its debt-to-equity ratio to 59.2%. Its total assets and total liabilities are PLN87.0M and PLN47.7M respectively. Biogened's EBIT is PLN8.4M making its interest coverage ratio 3.7. It has cash and short-term investments of PLN6.2M.

Key information

59.2%

Debt to equity ratio

zł23.29m

Debt

Interest coverage ratio3.7x
Cashzł6.16m
Equityzł39.32m
Total liabilitieszł47.66m
Total assetszł86.97m

Recent financial health updates

Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

Nov 06
Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

May 09
Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

Is Biogened (WSE:BGD) A Risky Investment?

Feb 01
Is Biogened (WSE:BGD) A Risky Investment?

We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Jun 30
We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Oct 08
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jun 29
Is Biogened (WSE:BGD) A Risky Investment?

Recent updates

Investors Give Biogened S.A. (WSE:BGD) Shares A 27% Hiding

Dec 06
Investors Give Biogened S.A. (WSE:BGD) Shares A 27% Hiding

Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

Nov 06
Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Aug 28
A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Aug 22
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

May 23
Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

May 09
Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Feb 21
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Is Biogened (WSE:BGD) A Risky Investment?

Feb 01
Is Biogened (WSE:BGD) A Risky Investment?

Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

Feb 01
Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Jun 30
We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Oct 08
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jun 29
Is Biogened (WSE:BGD) A Risky Investment?

Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

Mar 25
Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Dec 09
These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Jul 29
Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Apr 30
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jan 24
Is Biogened (WSE:BGD) A Risky Investment?

Financial Position Analysis

Short Term Liabilities: BGD's short term assets (PLN52.7M) exceed its short term liabilities (PLN23.4M).

Long Term Liabilities: BGD's short term assets (PLN52.7M) exceed its long term liabilities (PLN24.2M).

Debt to Equity History and Analysis

Debt Level: BGD's net debt to equity ratio (43.6%) is considered high.

Reducing Debt: BGD's debt to equity ratio has increased from 40.6% to 59.2% over the past 5 years.

Debt Coverage: BGD's debt is well covered by operating cash flow (20.1%).

Interest Coverage: BGD's interest payments on its debt are well covered by EBIT (3.7x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 15:14
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biogened S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution